Sir, Acute pancreatitis is a life-threatening condition affecting around 45 per 100 000 people annually. 1 The most common causes of acute pancreatitis are gallstone disease and chronic alcohol consumption, but in a large proportion of cases (10%-36%) the aetiology of acute pancreatitis cannot be determined. Although a number of frequently used drugs have been implicated in causing acute pancreatitis, the incidence of drug-induced acute pancreatitis is generally considered low (0.1%-5%). 2 Several common drugs, such as proton pump inhibitors, have been found to be predictors of acute pancreatitis in epidemiological studies. 3 The literature is scarce on the association of acute pancreatitis and triazole administration. We present this unusual case in which drug-induced pancreatitis symptoms were demonstrated following the fifth day of initiation of posaconazole treatment. In our patient, diagnosis of drug-induced pancreatitis was made by the compatible time of its initiation and exclusion of all common aetiologies of acute pancreatitis, such as alcohol, gallstones, hypercalcaemia, hypertriglyceridaemia or medical procedures, such as endoscopic retrograde cholangiopancreatography. After confirmation, the patient was treated by discontinuation of posaconazole and totally recovered.
A patient presented with severe epigastric pain and mild nausea 5 days after the introduction of posaconazole therapy for severe refractory mucositis. Her past medical history was psoriatic arthritis since 2004 treated with immunosuppressive therapy (anti-TNF, corticosteroids and leflunomide). She presented oropharyngeal and vaginal candidiasis iteratively treated with fluconazole. In November 2015, she presented Candida albicans-related vulvovaginitis, glossitis and stomatitis, which transiently responded (without total recovery) to the increasing fluconazole doses (400 mg once daily) and then recurred. In February 2016, she was prescribed posaconazole therapy (300 mg three times per day, tablet formulation). On the fifth day of initiation of posaconazole, the patient started feeling nauseous with epigastric pain. The pain was rated as severe, gnawing in nature and was radiating to the back. She was not an alcoholic, a smoker or a drug addict. The patient was haemodynamically stable. Physical examination revealed epigastric and right upper quadrant tenderness. Abdominal wall rigidity was absent. Laboratory evaluation was remarkable for serum lipase (289 IU/L; normal " 8-78). Liver function tests and lipid panel were within normal limits. An echo-endoscopy was performed and no proximal dilatation of the common bile duct or pancreatic duct was found. No common bile duct stone was seen. After ruling out common aetiologies of acute pancreatitis, drug-induced pancreatitis was diagnosed. The chronology of events made us suspect that posaconazole could be involved in the origin of the pancreatitis. Subsequently, posaconazole was discontinued after 20 days and the pain started to alleviate slowly and had disappeared 6 weeks after the beginning. A 3 month follow-up visit revealed complete recovery of the symptoms. The serum lipase level had returned to normal and abdominal MRI was unremarkable.
Drugs are a relatively rare cause of acute pancreatitis with an estimated incidence of 0.1%-5% of acute pancreatitis incidents. Some subpopulations, such as children, the elderly and patients with advanced HIV or chronic inflammatory disease, may be at higher risk. In literature reviews, various different drugs have been associated with pancreatitis. 4 To our knowledge, we report the first case of posaconazole-induced acute pancreatitis. For the other azoles, we found in the literature only four cases of drug-induced acute pancreatitis (two related to itraconazole use, one to voriconazole use and one to fluconazole use). [5] [6] [7] [8] Few data exist on the mechanism of drug-induced pancreatitis. Potential mechanisms for drug-induced acute pancreatitis include pancreatic duct constriction, cytotoxic and metabolic effects, accumulation of a toxic metabolite or intermediary and hypersensitivity reactions. 2 Negative effects of drugs, such as hypertriglyceridaemia and chronic hypercalcaemia, are also mechanisms for druginduced acute pancreatitis.
Posaconazole is an effective antifungal agent. Adverse effects include nausea, dizziness, headache, renal toxicity, neutropenia, hypertension, liver damage and allergic reactions. Pancreatitis has not been reported previously. In the Hachem et al.
9 study evaluating posaconazole as salvage treatment of invasive fungal infection in 65 patients with renal impairment, they reported one treatment discontinuation because of elevated pancreatic and liver enzyme levels without any clinical detail. Furthermore, in the study by Cornely et al.,
10 evaluating the safety of a posaconazole tablet formulation in 210 patients, no drug-induced pancreatitis was reported. In the present case, pancreatitis developed after oral administration of posaconazole at a supratherapeutic dose (300 mg three times per day), but the patient recovered rapidly after discontinuation of the drug. The safety study of a long-term posaconazole oral suspension (400 mg twice daily) in HIV patients with azole-refractory oropharyngeal candidiasis and/or oesophageal candidiasis demonstrated the long-term safety of the drug.
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Other factors associated with a higher risk of pancreatitis, such as drugs, alcohol and hyperlipidaemia, were not present. This suggests that the administration of posaconazole was the cause of pancreatitis. The present case seems to show that pancreatitis is a rare, but significant, complication stemming from treatment with posaconazole as it is for the other azoles.
In conclusion, we report this rare complication of posaconazole manifested in the form of drug-induced pancreatitis. Physicians should consider checking serum lipase levels in patients presenting with gastrointestinal symptoms, even as early as after a few days of posaconazole administration.
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We searched the databases of two Parisian hospital laboratories for patients with an unquantifiable VL although they were referred to the hospital for HIV care after a first positive HIV test. Patients were included if they claimed they were unaware of their infection until now, and if the western blot was positive for HIV-1 and negative for HIV-2. No ethics committee approval was required for this retrospective study.
Twenty-seven patients met the criteria over the last 4 years: 89% were originally from Africa. The demographic parameters and test results for these patients are summarized in Table 1 . VL was routinely determined with the Roche Cobas Ampliprep/Cobas TaqMan v2.0 assay (CTAM). A control test was possible for 12 patients and confirmed unquantifiable with the Abbott RealTime assay (ABB) ( Table 1) .
Two patients (nos 22 and 23) who had unquantifiable viraemia with both assays after .6 months of follow-up were considered to be elite controller patients. 2 Their serotyping tests confirmed HIV-1 group M infection, 3 and no antiretroviral drugs (ARV) were detected in their plasma. A woman (patient 21), was suspected to have stopped treatment before the HIV blood test, given the gradual increase in VL to 4.85 log copies/mL over three successive tests in a month. Four other patients (nos 24-27) did not return for subsequent consultations, making their follow-up too short (, 2 months) to determine whether they had recently stopped treatment or had elite controller status.
Finally, ARV intake was detected in the 20 remaining patients (74%): 18 of them had ARV detected in the plasma, and, at the second visit, two others (nos 19 and 20) admitted taking ARV. Some women said they were taking unknown drugs provided by a close friend/relative. The use of a false identity was suspected for three men. One of them (patient 16) retested negative for HIV antibody at a third visit and was believed to have sent an infected and treated person for the previous two blood tests. For the other two (patients 17 and 18), the same drugs were detected in plasma samples and CD4 cell counts were identical. Reverse transcriptase and protease genotyping on proviral DNA showed the sequences from these two patients to be 99.5% identical. By extending our search for similarities (Smartgene System) to the database of the same laboratory, containing data for .4500 patients, we identified four other patients with the same strain, which harboured only one or two nucleotide differences between the samples. These four additional patients were diagnosed with quantifiable viraemia several months before patients 17 and 18. Phylogenetic analysis and bootstrap confirmed the high degree of similarity of the HIV strains harboured by these six patients, 4 whose other biological parameters were also very similar. These patients each consulted only twice, always postponing blood sampling to another day and requesting a medical certificate, after which they were never seen again. These findings suggest that, rather than a transmission cluster, we are dealing here with a single person who returned for all the blood tests over a period of 2 years, with treatment initiation in the meantime. At the second visit, we asked two of these patients to undergo a fingerstick control test, to remove all possible doubt. They categorically refused, before leaving the consultation and never returning.
This study aimed to determine the reasons for which viraemia was sometimes not quantifiable at the time of HIV-1 diagnosis. No HIV-1 quantification discrepancy was observed between CTAM and ABB assays, confirming the efficiency of the
